KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amgen (AMGN) Non Operating Income (2016 - 2026)

Amgen has reported Non Operating Income over the past 18 years, most recently at $75.0 million for Q1 2026.

  • For Q1 2026, Non Operating Income fell 95.06% year-over-year to $75.0 million; the TTM value through Mar 2026 reached $1.2 billion, down 46.53%, while the annual FY2025 figure was $2.7 billion, 423.91% up from the prior year.
  • Non Operating Income for Q1 2026 was $75.0 million at Amgen, up from -$553.0 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $2.1 billion in Q3 2025 and troughed at -$782.0 million in Q4 2024.
  • A 5-year average of $308.9 million and a median of -$67.0 million in 2022 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: tumbled 4176.92% in 2022 and later surged 745.96% in 2025.
  • Year by year, Non Operating Income stood at -$67.0 million in 2022, then skyrocketed by 700.0% to $402.0 million in 2023, then crashed by 294.53% to -$782.0 million in 2024, then increased by 29.28% to -$553.0 million in 2025, then soared by 113.56% to $75.0 million in 2026.
  • Business Quant data shows Non Operating Income for AMGN at $75.0 million in Q1 2026, -$553.0 million in Q4 2025, and $2.1 billion in Q3 2025.